1. Scrip
  2. >>Business
  3. >>Earnings

AstraZeneca Q1: Tagrisso Beats Expectations And Drives Oncology Performance

 
• By Lucie Ellis-Taitt

Tagrisso shines for AstraZeneca in the first quarter and the company is on track for approval of a fifth new cancer drug, in line with 2014 promises made by CEO Pascal Soriot when the company rejected takeover offers from Pfizer.

Sun rays
Oncology portfolio shines for AstraZeneca in Q1 despite financial performance pressures • Source: Shutterstock

During the company's first-quarter earnings call, AstraZeneca PLC highlighted that a fifth new cancer drug since 2014 is on target for approval this year, and recently launched Tagrisso has become the best-selling product in its oncology portfolio. Later in the day, the UK firm also announced that Lokelma (sodium zirconium cyclosilicate, or ZS-9) had been approved by the US FDA to treat adults with hyperkalemia, a condition characterized by elevated potassium that particularly affects patients with chronic kidney disease and those on certain heart failure medicines.

AstraZeneca’s CEO Pascal Soriot made grand promises back in 2014 while fending off takeover bids for the company from US...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Blenrep Questions Won’t Go Away But GSK Sees Chance To Lead In COPD

 
• By Andrew McConaghie

GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.

Cipla Revs Up Biosimilars Engine Amid Winds Of Regulatory Change

 
• By Anju Ghangurde

Cipla’s partnered filgrastim biosimilar is expected to debut in the US in Q2 FY26 and the Indian firm expects an investment return ratio for its biosimilar engine “not too far” from that of a complex generic product amid an enabling regulatory environment.

Merck & Co.’s Winrevair Growing Into The Revenue Driver Needed Post-Keytruda LOE

 
• By Mandy Jackson

PAH drug Winrevair generated more than $1bn in sales in its first year on the US market, but the company plans to cut $3bn in costs through 2027 that it will reinvest in additional growth drivers.

Novo Selects Internal CEO To Recharge Growth

 
• By Jessica Merrill

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.

More from Business

Merck & Co.’s Winrevair Growing Into The Revenue Driver Needed Post-Keytruda LOE

 
• By Mandy Jackson

PAH drug Winrevair generated more than $1bn in sales in its first year on the US market, but the company plans to cut $3bn in costs through 2027 that it will reinvest in additional growth drivers.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By Joseph Haas

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Novo Selects Internal CEO To Recharge Growth

 
• By Jessica Merrill

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.